Dishman Carbogen Amcis Share Price Target 2026 Analyst Forecast Bull and Bear Case

Dishman Carbogen Amcis (NSE: DCAL) is a Pharmaceutical CDMO and APIs company trading at Rs 175.9 with a market capitalisation of Rs 2,813 crore. Analysts have set the Dishman Carbogen Amcis share price target at Rs 210 for 2026, based on FY27 earnings projections and sector re-rating potential. This article covers the complete 2026 price forecast including sector tailwinds, key risks, and bull and bear scenarios.

Click Here – Get Free Investment Predictions

Dishman Carbogen Amcis Share Price Target 2026: Key Takeaways

• Dishman Carbogen Amcis share price target 2026: Rs 210 (20% upside from CMP Rs 175.9)
• Bull case: Rs 255 | Bear case: Rs 140
• Ticker: DCAL | Sector: Pharmaceutical CDMO and APIs | MCap: Rs 2,813 crore
• 52W range: Rs 122 to Rs 289 | PE: 20x
• Key catalyst: Q4 FY26 results and FY27 earnings confirmation in 2026
• Key risk: FY27 earnings miss or FII outflows from Indian equities

Dishman Carbogen Amcis Company Overview

Dishman Carbogen Amcis (NSE: DCAL) is a Ahmedabad-based pharmaceutical CDMO manufacturing complex APIs, intermediates, and controlled substances for global innovator pharma companies, with integrated chemistry, manufacturing, and controls capabilities at Bavla and global sites. At CMP Rs 175.9 against a 52 week range of Rs 122 to Rs 289, the stock trades at a discount to its 52 week high. Market capitalisation is Rs 2,813 crore with trailing PE of 20x. Compared to peers in pharma CDMO like Divi’s Laboratories and Suven Pharma, Dishman Carbogen Amcis is positioned as a potential re-rating candidate toward the Rs 210 price objective on FY27 earnings delivery.

Parameter	Value
NSE Ticker	DCAL
Sector	Pharmaceutical CDMO and APIs
CMP (2026)	Rs 175.9
52 Week High	Rs 289
52 Week Low	Rs 122
Market Cap	Rs 2,813 crore
Trailing PE	20x
12-Month Analyst Target	Rs 210
Bull Case Target	Rs 255
Bear Case Target	Rs 140

Why Is the Dishman Carbogen Amcis Share Price Target Set at Rs 210 for 2026

FY27 Earnings Recovery and Revenue Acceleration

The Dishman Carbogen Amcis share price target of Rs 210 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results released in 2026 confirming the earnings trajectory are the most direct catalyst for a re-rating from CMP Rs 175.9. The Rs 210 price objective represents the base case with FY27 execution as the key variable.

Structural Sector Tailwinds in Pharmaceutical CDMO and APIs

The Pharmaceutical CDMO and APIs sector is expanding on the back of India’s domestic demand growth, PLI scheme support, and rising corporate investment. Dishman Carbogen Amcis’s market position among peers in pharma CDMO like Divi’s Laboratories and Suven Pharma creates a structural growth runway. Sustained sector outperformance is one of the key conditions for the Rs 255 bull case to materialise.

RBI Rate Cut Cycle and Lower Cost of Capital

India’s RBI rate cut cycle in 2026 is reducing borrowing costs and stimulating end market demand. Lower interest costs improve Dishman Carbogen Amcis’s EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 210 analyst consensus.

Union Budget 2026-27 Capex Push and Policy Support

Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex and PLI scheme continuity create a favourable policy backdrop for Dishman Carbogen Amcis’s Pharmaceutical CDMO and APIs operations, improving the probability of achieving the FY27 earnings targets that support the Rs 210 price objective.

FII Flow Normalisation After the 2026 Tariff Shock

As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 20x PE, Dishman Carbogen Amcis is positioned as a beneficiary of institutional reallocation, providing a tailwind toward the Rs 255 bull case over the medium term.

Dishman Carbogen Amcis Share Price Targets: Short Term, 12 Month, and Long Term

Short Term Dishman Carbogen Amcis Share Price Target

Near-term support for Dishman Carbogen Amcis is anchored close to the 52 week low of Rs 122. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating. Investors can use the 52 week low as an entry reference while awaiting FY27 earnings confirmation.

12-Month Dishman Carbogen Amcis Share Price Target 2026

The 12-month Dishman Carbogen Amcis share price target 2026 is Rs 210, implying approximately 20 percent upside from CMP Rs 175.9. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows. Track live on NSE ticker DCAL.

Long Term Dishman Carbogen Amcis Share Price Target: FY27 to FY28

The long term Dishman Carbogen Amcis share price target for FY27 to FY28 is Rs 255 in the bull case, requiring full earnings delivery, re-rating among peers in pharma CDMO like Divi’s Laboratories and Suven Pharma, and sustained institutional buying over a 2 to 3 year horizon.

Bull Case and Bear Case Scenarios for Dishman Carbogen Amcis in 2026

Bull Case Dishman Carbogen Amcis Share Price Target: Rs 255

The bull case Dishman Carbogen Amcis share price target of Rs 255 materialises when FY27 earnings beat analyst estimates, Pharmaceutical CDMO and APIs tailwinds accelerate, and FII flows return strongly to Indian equities, enabling re-rating toward higher peer multiples. From CMP Rs 175.9, this represents approximately 45 percent potential upside.

Bear Case Dishman Carbogen Amcis Share Price Target: Rs 140

The bear case Dishman Carbogen Amcis share price target of Rs 140 materialises if FY27 earnings disappoint or FII outflows depress the broader market, risking a test of the 52 week low support near Rs 122.

Scenario	Target	Key Conditions
Bull Case	Rs 255	FY27 beat, sector re-rating, FII inflows
Base Case (Analyst Target)	Rs 210	In-line FY27 delivery, partial FII recovery
Bear Case	Rs 140	FY27 miss, guidance cut, FII outflows

Key Risks That Could Derail the Dishman Carbogen Amcis 2026 Price Objective

Global Macro and US Tariff Headwinds

Prolonged tariff tensions and global demand slowdown remain prominent macro risks to the Dishman Carbogen Amcis share price target of Rs 210, with FII outflows being the direct transmission mechanism to Indian equity valuations.

FY27 Earnings Miss and Guidance Risk

An FY27 earnings miss or downward guidance revision would compress valuation multiples. This is the most direct company-specific risk to the Rs 210 analyst price objective. Investors must monitor quarterly results and management commentary closely.

Competitive Intensity Among Pharmaceutical CDMO and APIs Peers

Intensifying competition from peers in pharma CDMO like Divi’s Laboratories and Suven Pharma could compress Dishman Carbogen Amcis’s market share and pricing power. This structural risk must be weighed when assessing the defensibility of the earnings trajectory that underpins the Rs 210 analyst target for 2026.

Liquidity Risk and FII Selling Pressure

Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level improvement. Investors should size positions carefully and maintain stop losses to protect capital if broad market de-rating continues.

How to Invest in Dishman Carbogen Amcis

Check the Univest Screener for live data

Before considering any investment based on the Dishman Carbogen Amcis share price target of Rs 210, review Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, margin trends, and management commentary on Pharmaceutical CDMO and APIs sector demand and competition.

Open a Demat account with a SEBI registered stockbroker to trade Dishman Carbogen Amcis (NSE: DCAL) with regulatory protection. Study the competitive landscape among peers in pharma CDMO like Divi’s Laboratories and Suven Pharma before executing any position.

Plan your entry using the 52 week low of Rs 122 as a key support reference. A confirmed FY27 earnings uptick validates the entry case for the Rs 210 price target. Always set a stop loss below the 52 week low.

Restrict any single stock to 3 to 5 percent of your total equity portfolio, especially in the Pharmaceutical CDMO and APIs space where sectoral cycles can amplify volatility beyond initial expectations.

Always consult a SEBI registered financial advisor before investing. SEBI Registration No. INH000013776.

Download the Univest iOS App or the Univest Android App to track Dishman Carbogen Amcis’s live share price and receive daily stock recommendations.

FAQs on Dishman Carbogen Amcis Share Price Target 2026

What is the Dishman Carbogen Amcis share price target for 2026?

Ans. The Dishman Carbogen Amcis share price target 2026 is Rs 210, implying approximately 20 percent upside from CMP Rs 175.9. Bull case is Rs 255, bear case is Rs 140.

What was the Dishman Carbogen Amcis share price target for 2025?

Ans. The 2025 price objective for Dishman Carbogen Amcis was based on FY26 earnings projections. The current 2026 analyst consensus is Rs 210, reflecting FY27 growth potential from CMP Rs 175.9.

Is Dishman Carbogen Amcis a good investment at Rs 175.9?

Ans. At Rs 175.9, Dishman Carbogen Amcis offers potential upside toward Rs 210 if FY27 earnings recover. Consult a SEBI registered financial advisor before investing based on any price target.

What are the key risks to the Dishman Carbogen Amcis share price target 2026?

Ans. Key risks to the Dishman Carbogen Amcis share price target of Rs 210 include FY27 earnings miss, global tariff headwinds, FII outflows, and competitive pressure in Pharmaceutical CDMO and APIs. Monitoring quarterly results is essential.

What is the 52 week high and low of Dishman Carbogen Amcis?

Ans. The 52 week high of Dishman Carbogen Amcis is Rs 289 and the 52 week low is Rs 122. At CMP Rs 175.9, the stock is below its 52 week high and offers upside toward the Rs 210 price objective.

What are the main growth catalysts for Dishman Carbogen Amcis in 2026?

Ans. Key catalysts include FY27 PAT recovery, Pharmaceutical CDMO and APIs tailwinds, RBI rate cuts in 2026, Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.

How does Dishman Carbogen Amcis compare to its peers?

Ans. Dishman Carbogen Amcis operates in Pharmaceutical CDMO and APIs alongside peers in pharma CDMO like Divi’s Laboratories and Suven Pharma. At CMP Rs 175.9 with MCap Rs 2,813 crore, it is a potential re-rating candidate toward the Dishman Carbogen Amcis share price target of Rs 210 on FY27 delivery.

What is the Dishman Carbogen Amcis share price target for 2027?

Ans. The long-term Dishman Carbogen Amcis share price target for FY27 to FY28 is Rs 255 in the bull case, assuming earnings growth, sector re-rating, and FII inflows. Consult a SEBI registered financial advisor for personalised guidance.